Maternal plasma phosphatidylcholine fatty acids and atopy and wheeze in the offspring at age of 6 years by Pike, KC et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 474613, 13 pages
doi:10.1155/2012/474613
Research Article
Maternal Plasma Phosphatidylcholine Fatty Acids and Atopy and
Wheeze in the Offspring at Age of 6 Years
Katharine C. Pike,1, 2 Philip C. Calder,3, 4 Hazel M. Inskip,3, 5 SianM. Robinson,3, 5
Graham C. Roberts,1, 2, 3 Cyrus Cooper,3, 4, 5 KeithM. Godfrey,3, 4, 5 and Jane S. A. Lucas1, 2
1Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton S016 6YD, UK
2NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton and University Hospital Southampton
NHS Foundation Trust, Southampton S016 6YD, UK
3Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton S016 6YD, UK
4NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation
Trust, Southampton S016 6YD, UK
5Southampton Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton S016 6YD, UK
Correspondence should be addressed to Graham C. Roberts, gcr1@soton.ac.uk
Received 1 June 2012; Revised 13 July 2012; Accepted 25 July 2012
Academic Editor: Rocı´o Martı´n
Copyright © 2012 Katharine C. Pike et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Variation in exposure to polyunsaturated fatty acids (PUFAs) might influence the development of atopy, asthma, and wheeze. This
study aimed to determine whether diﬀerences in PUFA concentrations in maternal plasma phosphatidylcholine are associated with
the risk of childhood wheeze or atopy. For 865 term-born children, we measured phosphatidylcholine fatty acid composition in
maternal plasma collected at 34 weeks’ gestation. Wheezing was classified using questionnaires at 6, 12, 24, and 36 months and
6 years. At age of 6 years, the children underwent skin prick testing, fractional exhaled nitric oxide (FENO) measurement, and
spirometry. Maternal n-6 fatty acids and the ratio of n-3 to n-6 fatty acids were not associated with childhood wheeze. However,
higher maternal eicosapentaenoic acid, docosahexaenoic acid, and total n-3 fatty acids were associated with reduced risk of non-
atopic persistent/late wheeze (RR 0.57, 0.67 and 0.69, resp. P = 0.01, 0.015, and 0.021, resp.). Maternal arachidonic acid was
positively associated with FENO (P = 0.024). A higher ratio of linoleic acid to its unsaturated metabolic products was associated
with reduced risk of skin sensitisation (RR 0.82, P = 0.013). These associations provide some support for the hypothesis that
variation in exposure to n-6 and n-3 fatty acids during pregnancy influences the risk of childhood wheeze and atopy.
1. Introduction
Changes in dietary fat consumption have paralleled increases
in childhood asthma and atopy in industrialised countries
[1]. Consumption of oily fish, a source of long-chain n-
3 polyunsaturated fatty acids (PUFAs), has declined and
vegetable oils, a source of the n-6 PUFA linoleic acid (LA;
18:2n-6), have partly replaced animal fats [2–4]. As a result
of these changes, long-chain n-3 PUFA and saturated fat
intakes have decreased whilst LA intakes have increased
[2–4]. Epidemiological data suggest that dietary patterns
might influence allergic disease prevalence [1]. For example,
reduced asthma prevalence has been reported in children
who regularly eat fish [5, 6] and in the children of women
who have high fish or n-3 PUFA intakes during pregnancy [7,
8]. Conversely, a high intake of vegetable oil-based spreads, a
source of LA, is associated with an increased risk of asthma in
children [6, 9]. These observations suggest opposing actions
on n-6 and n-3 PUFAs on risk of asthma and allergy [10–12].
LA is converted to a longer chain more unsaturated n-6
PUFA arachidonic acid (AA; 20:4n-6) [13] which is the pre-
cursor of immunoregulatory eicosanoids like prostaglandin
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E2. The plant n-3 PUFA α-linolenic acid (ALA; 18:3n-
3) is converted to longer chain more unsaturated n-3
PUFAs including eicosapentaenoic acid (EPA; 20:5n-3) and
docosahexaenoic acid (DHA; 22:6n-3) [3, 13]. Conversion
of both LA and ALA to their more unsaturated derivatives
involves the same metabolic pathway [3, 13]. Thus a high
exposure to LA impairs the conversion of ALA, so favouring
synthesis of AA over EPA and DHA [13]. Therefore, the
balance of n-3 and n-6 PUFAs is considered to be important
[3, 13]. This balance might influence risk of atopy and
asthma via eﬀects upon prostaglandin E2 formation, with
consequences for T cell and B cell responses and allergic
sensitisation [10–12]. Like oily fish, fish oil is a source of EPA
and DHA. Maternal fish oil supplementation in pregnancy
has been shown to alter neonatal T-cell cytokine production
[14] and to reduce asthma risk in the oﬀspring [15].
However, supplementation of infants with fish oil seems not
to reduce allergic sensitisation or asthma [16, 17], although
studies of asthma-related outcomes in older children are
equivocal [18, 19]. As allergic sensitisation occurs early in
life, exposures at this time are most likely to influence
immune development. Some studies have suggested that
cord blood n-6 and n-3 PUFAs diﬀer between infants
according to personal or family history of atopy [20–23] and
have been interpreted as evidence of disturbed fatty acid
metabolism in atopic individuals [24]. However, studies of
small “high-risk” populations are poorly generalisable and
are often underpowered to assess clinical outcomes. More
recently, associations between maternal or cord blood PUFA
status and clinical outcomes have been sought prospectively
in large birth cohorts. One such study found a positive
association between the ratio of n-3 to n-6 PUFAs in mater-
nal plasma phospholipids and eczema in early childhood
[25]. In contrast, another study found inverse associations
between the ratio of n-3 to n-6 PUFAs in umbilical cord
blood red cells and both eczema and late-onset wheeze, a
sign of asthma [26], although the findings were regarded
as nonsignificant after adjusting for multiple comparisons.
Thus, currently the relationship between early exposure to
diﬀerent PUFAs and later outcomes related to atopy and
asthma is not clear and warrants further study. In particular,
it remains unclear whether natural variation in maternal
PUFA status influences childhood atopy or wheeze risk.
Here, we examine the relationship between maternal PUFA
status in late pregnancy and allergic disease in childhood.
The primary hypothesis being investigated is that high n-
6 PUFAs (individual and total), low n-3 PUFAs (individual
and total), and a low ratio of n-3 to n-6 PUFAs at 34 weeks’
gestation are associated with increased risk of childhood
atopy and wheeze. The secondary hypothesis is that a higher
ratio of precursor essential fatty acids to their unsaturated
metabolic products, suggestive of decreased conversion of
the plant-derived precursor PUFAs to their biologically active
derivatives, is associated with increased childhood atopy and
wheeze risk. Because of the mutual competition between
LA and ALA metabolism, a high exposure to LA would
be expected to increase the ratio of ALA to its derivatives.
Conversely, a lower exposure to LA would be expected to
decrease this ratio.
2. Methods
2.1. Study Population. Participants were mothers and chil-
dren in the Southampton Women’s Survey [27]. During
1998–2002, 12,583 20–34-year-old women were recruited;
those who became pregnant were followed up and their
children visited at ages 6, 12, 24, and 36 months and 6 years.
Infants born ≥ 35 weeks’ gestation were studied to exclude
abnormal lung development associated with prematurity.
1485 children born ≥ 35 weeks’ gestation were aged 6-
7 years during the study period 2006–2010; of these, 865
had both maternal PUFA measurements and 6-year follow-
up data (Figure 1). This study was conducted according
to the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were approved
by the Southampton and South West Hampshire Local
Research Ethics Committee (276/97, 307/97, 089/99, and
06/Q1702/104). Written informed consent was obtained
from all participant women for both their participation and
that of their child.
2.2.Maternal Plasma Phosphatidylcholine PUFAComposition.
Venous blood was sampled at 34 weeks’ gestation. Samples
were centrifuged and plasma stored at−80◦ C. Phosphatidyl-
choline (PC) is the major phospholipid in plasma. PC fatty
acid composition was determined by gas chromatography.
Plasma lipids were extracted using chloroform/methanol
(2 : 1) and PC separated by solid phase extraction (amino-
propylsilica Bond-Elut cartridge, Varian Inc., CA). PC fatty
acids were converted to methyl esters by heating with
sulphuric acid containing 2% methanol. Fatty acid methyl
esters (FAMEs) were extracted into hexane and concentrated
by evaporation under nitrogen. FAMEs were separated by
gas chromatography (Series 6890, Hewlett Packard, BPX 70
column SGE Europe Ltd.) and were identified by comparing
retention times with those of authentic standards. Data are
expressed as percentage concentration (g/100 g total fatty
acids). Ten fatty acid exposures were calculated: total n-
3 and n-6 PUFAs as percentage of total fatty acids and
the ratio of total n-3: total n-6 PUFAs; percentages of the
essential n-3 precursor ALA, the essential n-6 precursor
LA, the n-3 products of ALA metabolism EPA and DHA,
and the n-6 product of LA metabolism AA; the ratios of
essential fatty acid precursors (i.e., LA or ALA) to their
unsaturated products for both the n-3 and n-6 PUFA families
(ALA/(20:4n-3 + EPA + 22:5n-3 + DHA) and LA/(18:3n-6 +
20:3n-6 + AA + 22:4n-6 + 22:5n-6)). For the latter, a high
ratio is a proxy indicator of lower conversion eﬃciency of the
essential fatty acid precursor to its unsaturated products.
2.3. Atopy. Skin prick testing was used to identify immuno-
logic sensitization to a range of common allergens; such
sensitization is termed atopy. Skin prick testing was con-
ducted in the children at age of 6 years in their homes
using cat, dog, house dust mite, egg, milk, and grass and
tree pollen allergens. Skin prick tests were considered valid if
positive and negative control wheals were≥3mm and 0mm,
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Excluded as preterm n = 44
Children born at ≥
gestation n = 1485
Excluded as missing data n = 620
Missing 6-year follow-up only 517
Missing fatty acid data only 49
Missing both 54
Mother-child pairs with both 6-year follow-up and fatty acid data
n = 865
Skin sensitisation data
complete n = 638
Sensitised 160
Not sensitised 478
Wheeze data complete n = 861
Transient wheeze 368
Persistent/late wheeze 137
Never wheezed 356
Other respiratory data
Spirometry 702
FENO 452
Children born to women within the
survey aged 6-7 years
between 2006 and 2010 n = 1529
35 weeks
Figure 1: Study outline.
respectively. Atopy was defined as a wheal ≥3mm to any
allergen.
2.4. Airway Inflammation. Upon attaining their sixth birth-
days, children were invited to a clinical visit. Those attending
attempted fractional exhaled nitric oxide (FENO) measure-
ment, an indicator of the extent of airways inflammation.
FENOwasmeasured using a NIOX chemiluminescence anal-
yser (Aerocrine, Sweden) according to the recommendations
of European Respiratory Society-American Thoracic Society
[28, 29]. Mean FENO was calculated, where possible, from
three readings.
2.5. Childhood Wheeze. Wheezing occurs when lower air-
ways are narrow or constricted which may be due to asthma
or to other lower respiratory conditions. Transient wheezing
is common in young children, often due to the presence
of an infection and usually stops altogether after about 3
years of age. Persistent wheezing is where wheezing continues
beyond the preschool years; these children are more likely
to have allergies and to develop asthma than those whose
wheezing stops. Late-onset wheezing is where the wheeze
does not develop until beyond the preschool years; again
these children are more likely to have allergies and to develop
asthma. Research nurses administered questions from the
“International Study of Asthma and Allergies in Childhood”
core questionnaire wheezing module [30] to the children’s
parents when the children were aged 6, 12, 24, and 36months
and 6 years. Mothers were asked whether their child had
had ‘any episodes of chestiness associated with wheezing or
whistling in his/her chest since they were last seen?’ The
results were combined to define
(i) transient wheeze: wheeze at 6, 12, 24, or 36 months
but no wheeze at 6 years and no asthma treatment at
6 years;
(ii) persistent wheeze: wheeze at 6, 12, 24, or 36 months,
plus wheeze at 6 years or asthma treatment at 6 years;
(iii) late-onset wheeze: no wheeze at 6, 12, 24, or 36
months, plus wheeze at 6 years or asthma treatment
at 6 years.
The persistent and late-onset wheeze groups were com-
bined as few children wheezing at 6 years did not wheeze
before 36 months. Persistent/late wheeze was subclassified
according atopic status established through skin prick test-
ing.
2.6. Lung Function. Spirometry was performed at age 6
years in the children’s homes according to the American
Thoracic Society guidelines [31, 32]; to avoid discomfort
nose clips were not used. Flow-volume loops were measured
using a Koko spirometer with incentive software. Absolute
forced expiratory volume at 1 second (FEV1) values were
recorded without height standardisation because it was
believed possible that any eﬀect of maternal PUFA status
upon childhood airway dimension, and hence wheeze risk
might be mediated by an eﬀect upon childhood height.
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2.7. Statistical Methods. Poisson regression with robust vari-
ance was used to model relative risk for binary outcomes.
This approach is appropriate for common outcomes where
odds ratios derived from logistic regression cannot be
interpreted as relative risks [33]. As the transient and
persistent/late wheeze phenotypes were mutually exclusive,
children suﬀering one of these types of wheeze could not
be regarded as at risk of the other. For this reason, relative
risks were calculated by comparing children with transient
or persistent/late wheeze to those who had never wheezed.
Persistent/late wheeze with atopy is believed to be a separate
phenotype to persistent/late wheeze without atopy diﬀering
not only in clinical presentation but likely also in aetiology.
Relative risks for these phenotypes were calculated using
nonatopic children who had never wheezed as the com-
parator group. Relationships between maternal PUFAs and
continuous outcomes were explored using linear regression.
An inverse square root transformation was used to normalise
FENO data. For ease of interpretation, transformed FENO
values were standardised and the sign switched so that high
untransformed FENO values gave rise to high standardised
scores.
The variables listed in Table 1 were considered potential
confounders a priori except birth weight and gestational
age as these factors may causally link maternal PUFA status
and childhood outcomes. Potential confounders were tested
for association with each respiratory outcome and models
developed comprising all variables associated with each out-
come; for this reason, diﬀerent outcomes will have diﬀerent
confounders. Exposure variables were standardised so that
each variable was on the same scale so that relative risks could
be compared as change in risk per one standard deviation
increment in each exposure variable. The assumption of
linearity was confirmed using a quadratic term to exclude a
nonlinear, or U-shaped, association.
Interpretation of the analyses is complicated by the
number of statistical tests made, and the conventional
P value of 0.05 should be interpreted with caution. How-
ever, because the analyses were designed a priori to test
specific hypotheses and not all the tests were independent,
a Bonferroni correction would be over-conservative [34].
We therefore focused primarily on results with P values
≤0.025 and considered the consistency of the findings in our
interpretation. Analyses were completed using Stata 11 (Stata
Corp., College Station, TX).
3. Results
3.1. Participants. PUFA data were available for 865 (94.6%)
of the 914 mother-child pairs with 6 year follow-up data. The
865 mother-child pairs included in the study were broadly
similar across a number of demographic characteristics to
those missing either PUFA or follow-up data (Table 1). Study
mothers were, however, slightly older, less likely to smoke in
pregnancy and of higher education and social class, whilst
study children were less likely to be exposed to tobacco smoke
in infancy and more likely to have been breast fed than those
without follow-up or fatty acid data (Table 1).
Suﬃcient questionnaire data were available to classify 856
children according to wheeze status; of these 635 children
consented to skin prick testing and had valid results. 160
(25.1%) study children were classified as atopic; 368 (42.7%)
had transient and 137 (15.9%) persistent/late wheeze. 94
children in the persistent/late group were characterized
according to atopic status, of these 50.0% were atopic and
50.0% nonatopic (Table 2). These data are comparable to
other cohorts in the United Kingdom [35, 36]. The median
percentage PUFA concentrations values (Table 3) were com-
parable to published data from a similar gestation [37].
Acceptable FEV1 and FENO measurements were available
from 702 and 452 children, respectively.
3.2. Maternal Late-Pregnancy PUFAs and Childhood Wheeze.
Total maternal n-3 and n-6 PUFA percentages and the ratio
of n-3 to n-6 PUFAs were not associated with any childhood
wheeze phenotype (Table 4). The ratio of the n-3 fatty acid
precursor (ALA) to its unsaturated metabolic products had
weak positive associations with transient wheeze (adjusted
RR 1.08, P = 0.03) and with persistent/late wheeze risk
(adjusted RR 1.14, P = 0.03) (Table 4). The latter association
was significant in nonatopic children only (adjusted RR 1.46,
P = 0.010) (Table 5). A similar weak positive association
was found between this ratio and transient wheeze (adjusted
RR 1.08, P = 0.03) (Table 4). Significant inverse associations
were found between total n-3 PUFAs, DHA and EPA, and
nonatopic persistent/late wheeze (adjusted RR 0.69, P =
0.021; adjusted RR 0.67, P = 0.015; adjusted RR 0.57,
P = 0.014) (Table 5). EPA, DHA, and total n-3 PUFAs had
weak inverse associations with atopic persistent/late wheeze
(adjusted RR 0.65, P = 0.04; adjusted RR 0.74, P = 0.05;
adjusted RR 0.72, P = 0.03) (Table 5). A significant inverse
association was found between maternal AA and nonatopic
persistent/late wheeze (adjusted RR 0.76, P = 0.023). There
was no evidence for a significant association between total
n-6 PUFAs and any wheeze phenotype, and the ratio of the
n-6 fatty acid precursor (LA) to its unsaturated metabolic
products had no significant associations with any wheeze
outcome.
3.3. Maternal Late-Pregnancy PUFAs and Childhood Atopy.
A higher ratio of the n-6 fatty acid precursor (LA) to
its unsaturated metabolic products was associated with a
decreased risk of childhood skin sensitisation (adjusted RR
0.82, P = 0.013) (Table 6). The n-6 fatty acid AA was
not significantly associated with skin sensitisation and no
significant associations were found for any other PUFA or
ratio of PUFAs examined.
3.4. Maternal Late-Pregnancy PUFAs and Childhood FENO.
No associations were found between total n-3 or n-6 PUFAs
or the ratio of n-3 to n-6 PUFAs and FENO (Table 6).
However, maternal AA and FENO were positively associated
(P = 0.024).
3.5. Maternal Late-Pregnancy PUFAs and Childhood FEV1.
None the PUFAs, nor any of the fatty acid ratios, examined
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Table 1: Comparison of SWS mother-child pairs with complete data with those lacking either maternal fatty acid or 6-year follow-up data
but born in the same time period.
Mother-child pairs in analysis
(n = 865)
Mother-child pairs with missing data
(n = 620) P
Maternal characteristics
Age at child’s birth (mean (SD)) 30.4 (3.8) 29.6 (3.8) 0.0003
Primiparous (n (%))
No 463 (53.5) 368 (59.4) 0.03
Yes 402 (46.5) 252 (40.6)
Education attainment (n (%))∗ <0.001
None 14 (1.6) 35 (5.7)
GCSE D–G 84 (9.7) 67 (10.8)
GCSE A∗–C 248 (28.7) 179 (28.9)
A Level 251 (29.1) 184 (29.7)
HND 64 (7.4) 40 (6.5)
University degree 203 (23.5) 114 (18.4)
Parents’ social class (n (%))† 0.01
I 91 (10.6) 54 (11.7)
II 427 (49.9) 199 (43.3)
III Nonmanual 234 (27.4) 123 (26.7)
III Manual 67 (7.8) 54 (11.7)
IV 34 (4.0) 23 (5.0)
V 2 (0.2) 7 (1.5)
Smoked in pregnancy (n (%)) <0.001
No 728 (85.5) 464 (78.0)
Yes 123 (14.5) 131 (22.0)
Maternal asthma (n (%)) 0.2
No 676 (78.8) 465 (76.1)
Yes 182 (21.2) 146 (23.9)
Maternal childhood eczema (n (%)) 0.7
No 706 (82.4) 498 (81.5)
Yes 151 (17.6) 113 (18.5)
Maternal rhinitis (n (%)) 0.3
No 497 (57.9) 369 (60.4)
Yes 361 (42.1) 242 (39.6)
Prepregnancy BMI, kg/m2 (median, IQR) 24.3 (22.0–27.6) 24.0 (21.9–27.3) 0.5
Total energy intake, kcal (median, IQR) 2301 (1919–2748) 2354 (1958–2779) 0.08
Paternal characteristics
Paternal asthma (n (%)) 0.5
No 699 (82.1) 484 (80.8)
Yes 152 (17.9) 115 (19.2)
Paternal childhood eczema (n (%)) 0.9
No 743 (88.2) 527 (88.1)
Yes 99 (11.8) 71 (11.9)
Paternal rhinitis (n (%)) 0.5
No 599 (66.3) 399 (66.5)
Yes 284 (33.7) 201 (33.5)
Child’s characteristics
Gender (n (%)) 0.5
Male 447 (51.7) 331 (53.6)
Female 418 (48.3) 287 (46.4)
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Table 1: Continued.
Mother-child pairs in analysis
(n = 865)
Mother-child pairs with missing data
(n = 620) P
Birth weight, kg (mean (SD)) 3.49 (0.50) 3.46 (0.50) 0.4
Gestational age, weeks (mean (SD)) 39.9 (1.4) 39.9 (1.5) 0.6
Months of breastfeeding (n (%)) <0.001
None 133 (15.4) 130 (23.5)
<1 170 (19.7) 113 (20.4)
1–3 153 (17.7) 119 (21.5)
4–6 153 (17.7) 70 (12.6)
7–11 143 (16.6) 81 (14.6)
12 or more 111 (12.9) 41 (7.4)
Age of introduction solid food, weeks (median (IQR)) 17.0 (15–18) 17 (15–18) 0.3
Mother smoking during child’s infancy (n (%)) 0.003
No 712 (83.0) 434 (76.7)
Yes 146 (17.0) 132 (23.3)
Cats/dogs in home during child’s infancy (n (%)) 0.5
No 438 (50.8) 290 (52.8)
Yes 424 (49.2) 259 (47.2)
Numbers do not always add to the full column totals due to missing data
Binary outcomes were compared by χ2 test, categorical outcomes by a χ2 test for trend, and continuous variables using t-tests, after transformation where
appropriate, or a ranksum test.
∗GCSE General certificate of secondary education, high school education (to age 16) graded from G (low) to A∗ (high), A level Advanced-level high school
education (to age 18), HND Higher national diploma higher education qualification of slightly lower level than that of a university degree.
†Social class graded from V (low) to (I) high according to occupation.
Table 2: Distribution of participants between outcome groups.
Outcome N %
Never wheezed 356 41.3
Transient wheeze 368 42.7
Persistent/late wheeze 137 15.9
Persistent/late wheeze with atopy 47 7.4
Persistent/late wheeze without atopy 47 7.4
Skin sensitisation 160 25.1
Wheeze classification possible for 861 children, skin sensitisation data
available for 638, and both wheeze and skin sensitisation data available for
635.
was significantly associated with childhood FEV1 (Table 7).
FEV1 was uncorrected for height due to concerns that height
might mediate any association between maternal fatty acids
and airway geometry; however, including child’s height in the
multivariate analysis did not alter the findings (results not
shown).
4. Discussion
In this study we found some limited support for our primary
hypothesis linking relatively low levels of maternal n-3
compared to n-6 PUFAs with later wheeze and atopy. Higher
maternal EPA, DHA, and total n-3 PUFAs at 34 weeks’
gestation were associated with a lower risk of persistent/late
wheeze at age of 6 years. This association was only significant
in nonatopic children, and there was no association between
total n-3 PUFAs, total n-6 PUFAs or the ratio of n-3
to n-6 PUFAs, and childhood atopy as measured by skin
sensitisation. However, maternal AA, a metabolic product of
the essential n-6 precursor LA, was significantly positively
associated with FENO, a marker of airways inflammation.
Associations may reflect a direct action of intrauterine PUFA
supply upon fetal development. Alternatively associations
may occur as a consequence of dietary patterns or metabolic
disturbance shared by mothers and their children. Little
support was found for the secondary hypothesis, although
the ratio of ALA to its unsaturated metabolic products was
positively associated with persistent/late wheeze in nonatopic
children and the ratio of LA to its unsaturated metabolic
products was inversely associated with skin sensitisation at
6 years. However, these findings cannot easily be interpreted
as evidence for decreased precursor conversion in atopic
disease.
The inverse associations between total maternal EPA,
DHA, and total n-3 PUFAs and childhood persistent/late
wheeze in the group as a whole, but particularly in those
without atopy, are consistent with the idea that highly
unsaturated n-3 fatty acids might protect against childhood
wheeze, as suggested by Black and Sharpe [10]. However,
only the associations with nonatopic persistent/late wheeze
were significant, and no significant association was found
between maternal n-3 PUFAs and skin sensitisation or atopic
persistent/late wheeze. There was no evidence that higher
maternal n-6 PUFAs increased the oﬀspring’s risk of wheeze
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Table 3: Fatty acid composition of maternal plasma PC measured at 34 weeks’ gestation.
Fatty acid exposure Median 25th and 75th percentiles
Total n-3 PUFAs % 5.01 4.34, 5.84
ALA % 0.29 0.22, 0.36
DHA % 3.78 3.25, 4.41
EPA % 0.36 0.27, 0.48
Total n-6 PUFAs % 35.4 34.0, 36.8
LA % 23.1 21.6, 24.7
AA % 7.67 6.79, 8.54
Total n-3 : n-6 PUFAs 0.14 0.12, 0.17
Ratio of ALA to its unsaturated metabolic products 0.06 0.04, 0.08
Ratio of LA to its unsaturated metabolic products 1.87 1.66, 2.14
N = 865.
ALA: alpha-linolenic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid.
or skin sensitisation. Whilst these results do not support
competing eﬀects of n-3 and n-6 PUFAs upon allergic skin
sensitisation or the original Black and Sharp hypothesis [10],
the positive association between maternal AA concentration
and FENO suggests that eosinophilic airways inflammation
is higher in the children of mothers with high AA status.
A previous study found no association between maternal
or umbilical cord AA and atopy, although the study included
less than 300 mother-child pairs and did not consider
objective measures of atopy such as skin sensitization [38].
The weak inverse association between AA and persistent/late
wheeze in nonatopic children found in the current study,
however, contradicts the hypothesised association between
high levels of n-6 PUFAs and asthma. Although this finding
was unexpected and may have occurred by chance, inverse
associations have previously been found between AA and
risk of atopy in adults [24, 39] and in infants [20, 22]. This
finding is also comparable to an inverse association found
previously between the maternal ratio of n-6 to n-3 long-
chain PUFAs and childhood eczema [25].
The ratio of ALA to its unsaturated metabolic products
was significantly positively associated with nonatopic persis-
tent/late wheeze and weakly with transient wheeze. These
results are compatible with the suggestion of altered fatty
acid metabolism in mothers of children who later develop
allergic disease [21], and also with genetic data linking
polymorphisms in the gene clusters coding for fatty acid
desaturases and the prevalence of allergic rhinitis and atopic
eczema [40]. However, given that no associations were found
between this ratio and skin sensitisation or persistent/late
wheeze with atopy, there was no evidence that ineﬃciency
in ALA metabolism is associated with childhood wheeze
as a consequence of allergic sensitisation. However, the
inverse association between the ratio of LA to its unsaturated
metabolic products and skin sensitisation might indicate
altered LA metabolism in the mothers of children who later
develop atopy compared to mothers of nonatopic children.
The direction of this association does not appear to support
a link between decreased fatty acid desaturase activity and
childhood atopy, although definitive assertions about flux
through pathways cannot be made without stable isotope
studies.
The current study has some limitations. Although a
priori hypotheses were examined, due to the number of
associations tested, unwarranted biological significance may
be attributed to false positive results. Response bias cannot
be excluded as the entire original cohort was not followed
up; this would only invalidate the study’s conclusions,
however, if the relationship between maternal PUFA status
and childhood outcomes diﬀered between study participants
and those with missing data. A broad range of potential
confounders were considered but residual confounding
cannot be excluded. We were unable to correct for maternal
PUFA status earlier in pregnancy, for breast milk fatty acid
composition, or for the children’s PUFA intake and status in
postnatal life, which are all likely to be factors contributing
to immune development and allergy risk in childhood. It is
also unclear whether suﬃcient variation in exposure exists
within this population to meaningfully aﬀect outcomes; less
than 1% of the mothers in this study reported an intake of
at least one fatty fish meal per week, the intake providing
the n-3 PUFA dose administered in a successful fish oil
intervention trial [15]. Epidemiological studies are further
complicated by the multiple asthma phenotypes thought to
exist, as these may show diﬀerent patterns of association with
early life influences. Heterogeneity within study outcomes is
likely, and this may decrease the study’s sensitivity. A final
limitation is that we measured the fatty acid composition
of maternal plasma PC, the major phospholipid in the
bloodstream. Although this has the advantage that plasma
PC fatty acids are influenced by dietary intakes and that
the context of the Black and Sharp hypothesis is an eﬀect
of maternal diet on later risk of allergy and asthma [10],
plasma phospholipids are not the principal vehicle for supply
of fatty acids from the maternal circulation to the fetus
[41]. For this reason, the fatty acid composition of maternal
plasma triacylglycerols and nonesterified fatty acids would
also be useful to measure, although the PUFAs in the former
correlate strongly with those in plasma PC, as would the fatty
acid composition of cord blood plasma lipids.
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Table 7: Regression coeﬃcients for the association between standardised values (z-scores) of maternal plasma PC fatty acids and FEV1 at 6
years of age.
Change in FEV1 (L/s) per SD change of each fatty acid exposure variable
Maternal exposure Unadjusted analysis n = 702 Adjusted∗ analysis n = 702
Beta (95% CI) P Beta (95% CI) P
Total n-3 PUFAs % 0.013 (−0.001, 0.028) 0.07 0.010 (−0.004, 0.024) 0.15
ALA % −0.012 (−0.026, 0.003) 0.11 −0.009 (−0.024, 0.005) 0.18
DHA % 0.011 (−0.003, 0.026) 0.12 0.008 (−0.006, 0.022) 0.28
EPA % 0.016 (0.001, 0.030) 0.03 0.013 (−0.001, 0.027) 0.07
Total n-6 PUFAs % 0.000 (−0.015, 0.014) 0.96 0.000 (−0.014, 0.014) 0.99
LA % −0.004 (−0.019, 0.011) 0.59 −0.005 (−0.019, 0.009) 0.50
AA % −0.001 (−0.016, 0.013) 0.84 0.000 (−0.014, 0.015) 0.99
Total n-3 : n-6 PUFAs ratio 0.013 (−0.001, 0.027) 0.08 0.010 (−0.004, 0.024) 0.16
ALA: unsaturated metabolic products −0.016 (−0.031, −0.002) 0.03 −0.011 (−0.026, 0.003) 0.12
LA: unsaturated metabolic products −0.007 (−0.022, 0.008) 0.36 −0.008 (−0.023, 0.006) 0.25
Unadjusted and adjusted analyses for each maternal variable are presented.
RR: relative risk; ALA: alpha-linolenic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid. Beta derived
from linear regression.
∗Adjusted for parity and child’s sex and age.
In summary, measurement of maternal PUFAs in a
large population-based cohort enabled us to investigate
hypotheses linking PUFA exposure during late-pregnancy
to childhood wheeze and atopy. An inverse association was
found for maternal EPA, DHA, and total n-3 PUFAs and
the relative risk of persistent/late nonatopic wheeze whilst
high maternal AA was associated with increased FENO, a
marker of airways inflammation. Together with a number
of weaker associations, albeit with small eﬀect sizes, these
results provide some support for a protective link between
the maternal n-3 PUFAs and wheeze and atopy in childhood.
Support for the suggested role of n-6 PUFAs was minimal.
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